Transcription of 平成24年3月期 第1四半期決算 ... - takeda.co.jp
1 24 23 29 4502 (03)3278-2037 23 12 24 23 23 30 (1) 24 357,219 116,210 119,236 75,584 23 354,698 107,261 103,834 64,111 24 51,322 23 9,424 24 23 (2) 24 2,713,566 2,116,407 2, 23 2,786,402 2,136,656 2, 24 2,071,025 23 2,091,589 23 24 24 ( ) 24 23 24 31 ( ) ( ) 720,000 220,000 220,000 140,000 1,450,000 390,000 395,000 250,000 (1) (2) ( ).
2 (3) ( ) . (4) ( ) 24 789,666,095 23 789,666,095 24 264,650 23 295,436 ( ) 24 789,378,045 23 789,379,353 12 23 19 /29( ) ( ) 24.
3 2 (1) ..2 (2) ..7 (3) ..8 ..9 (1) ..9 (2) ..9 (3) ..9 ..10 (1) ..10 (2) ..12 ..12 ..13 (3) ..14 (4) ..14 (5) ..15 (6) ..15 ..16 (1) ..16 (2) ..16 (3) ..17 (4) ..17 (5) ..18 - 1 - ( ) 24 2010 11-13 Innovation Culture Growth 2009 II 100
4 11-13 28 70 - 2 - ( ) 24 100 AFSSAPS EMA CHMP FDA EMA CHMP EMA EMA 230 2009 [ ]
5 2009 2010 2010 OD 2010 11 2011 2011 [ ] 2009 2009 2010 XR( ) 2011 [ ] 2010 - 3 - ( ) 24 2011 4-6 25 3,572 100 161 931 64 586 21 321 66 301 22 141 9 89 1.
6 162 33 122 44 78 154 1,192 65 3,572 25 ( ) 1,162 89 ( ) 1,192 154 ( ) 756 115 ( ) - 4 - ( ) 24 115 756 1 14 53 95 75 12 90 110 06 2011 4-6 3,199 18 1,089 77 1,482 78 1,717 60 149 11 40 5 236 4 38 7 3,572 25 1,162 89 18 3,199 77 1,089 78 ( 1.)
7 482 360 14 187 14 167 4 115 7 103 12 60 1,717 - 5 - ( ) 24 11 149 40 236 38 [ ] MLN4924 16 MLN9708 16 TAK-875 71 FDA 2 SYR-322 SYR-322 FDA [ ] - 6 - ( )
8 24 [ ] AMG479 LuAA21004 * FDA * SGN-35 brentuximab vedotin ADCETRISTM EMA 16 7,136 728 5,972 526 1,164 202 - 7 - ( )
9 24 23 11 24 7,200 2,200 2,200 1,400 14,500 3,900 3,950 2,500 85 120 23 19 11-13 2012 2012 12 2010 12 22 - 8 - ( ) 24 22 30 22 30 1 - 9 - ( ) 24 (1) ( ) ( 23 31 ) ( 23 30 )
10 217,897 191,266 293,995 299,820 656,321 629,078 59,668 61,465 39,899 39,949 37,560 38,446 229,909 219,861 51,894 64,459 891 889 1,586,252 1,543,455 407,480 403,219 217,123 207,555 293,131 275,007 7,173 6,755 517,427 489,316 165,019 168,477 110,419 109,255 196 156 275,242 277,576 1,200,150 1,170,111 2,786,402 2,713,566 - 10 - ( ) 24 ( ) ( 23 31 ) ( 23 30 ) 83,065 75,651 1,345 1,270 41,977 32,379 43,520 44,421 9,471 9,924 257,218 225,791 436,596 389,436 112,295 105,511 16,805 16,813 6,779 6,282 77,271 79,118 213,150 207,723 649,746 597,159 63,541 63,541 49,638 49,638 2,272,067 2,276,555 1,014 869 2,384,232 2,388,865 73,944 76,226 17 4,283 366,604 398,350 292,643 317.
